Related Experiment Video

Updated: Mar 28, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

SSTR-based therapies for gastroenteropancreatic and thoracic neuroendocrine neoplasms

Simona Grozinsky-Glasberg1, Beata Kos-Kudla2

  • 1Neuroendocrine Tumor Unit, ENETS Centre of Excellence, Division of Medicine, Hadassah Medical Organization and Faculty of Medicine, the Hebrew University, Jerusalem 91120, Israel.

Endocrine Reviews
|March 27, 2026
PubMed

Insights

Somatostatin (SRIF) and its receptors (SSTR) are crucial for neuroendocrine neoplasms (NEN). This review explores current and future somatostatin receptor-targeted ligand (SRL) therapies, addressing unmet needs in NEN treatment.

Area of Science:

  • Endocrinology and Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Somatostatin (SRIF) and its receptors (SSTR) play a critical role in neuroendocrine neoplasms (NEN) management.
  • Current standard-of-care somatostatin receptor-targeted ligand (SRL) therapies have limitations and unmet needs in NEN treatment.

Purpose of the Study:

  • To provide a concise review of the evolving field of SRL in NEN.
  • To highlight new and ongoing developments and potential novel therapeutic approaches.
  • To identify knowledge gaps in SRL for NEN routine practice.

Main Methods:

  • Literature review focusing on pathophysiology of SSTR in NEN.
  • Assessment of current knowledge on standard-of-care SRL.
  • Analysis of ongoing and future research in SRL for NEN.

Main Results:

  • Insights into SSTR pathophysiology and its relation to SRL efficacy limitations.
  • A state-of-the-art overview of current SRL therapies for NEN.
  • Identification of areas requiring further research for SRL in NEN.

Conclusions:

  • The field of SRL for NEN is rapidly advancing, with novel approaches emerging.
  • Addressing unmet needs requires a deeper understanding of SSTR pathophysiology and continued research into novel SRL.
  • Future research should focus on identified knowledge gaps to improve SRL efficacy in NEN management.
Keywords:
NENNETSRIFSSTRagonistcarcinoidligandneuroendocrine neoplasmssomatostatinsomatostatin receptors

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
744
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding01:15

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
1.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
811